Investors

  • 메인

  • Investors

Overview

INGENIA Therapeutics is pioneering a new paradigm in vascular normalization
and remains committed to enhancing corporate value through sustainable
growth and responsible management.

Stock Information

  • INGENIA Therapeutics 950260
  • Current Price -
    • Price Change 0 (+0%)
    • Trading Value -
    • Trading Volume(Shares) -

As of 3:39 PM (KST), May 14, 2026

Open -
Upper Limit -
Lower Limit -

Shareholding Structure

Category Number of DRs Ownership(%)
Existing Investors 34,030,767 68.8
Major Shareholder & Related Parties 10,158,344 20.6
Public Shareholders 5,300,000 10.6
Total 49,489,111 100.0

Financial Information

Summarised Consolidated Statement of Profit or Loss

(Unit: USD)
Category FY2025 FY2024 FY2023
Sales 2,186,638 2,607,791 1,858,984
Operating Profit 104,374 54,880 57,032
Profit Before Income Tax 222,675 61,432 134,813
Net Income 185,319 55,163 134,241
Total Comprehensive Income 233,675 53,827 117,979

Summarised Consolidated Statement of Financial Position

(Unit: USD)
Category FY2025 FY2024 FY2023
Current Assets 1,511,630 1,360,261 1,256,460
Non-current Assets 1,709,296 1,581,788 1,555,846
Total Assets 3,220,926 2,942,049 2,812,306
Current Liabilities 733,533 619,136 583,192
Non-current Liabilities 125,088 172,242 128,457
Total Liabilities 858,641 791,379 711,649
Total Equity 2,362,284 2,150,670 2,100,656

Summarised Consolidated Statement of Cash Flows

(Unit: USD)
Category FY2025 FY2024 FY2023
Operating Activities 106,227 54,602 144,128
Investing Activities (70,954) (117,369) (199,229)
Financing Activities 8,044 65,836 63,247
Net Increase in Cash 43,317 3,069 8,146
Beginning Cash Balance 306,476 299,258 293,036
FX Effect (1,228) 4,149 (1,924)
Ending Cash Balance 348,565 306,476 299,258